person · Reporting owner

Jones Nicole S

Disclosed activity across 3 companies

Tapewire entity: 21248
SEC CIK: 0001492663

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Cigna GroupCI · Entity 550	See Remarks	August 18, 2026	August 20, 2026
FTI CONSULTING, INCFCN · Entity 4028	Director	June 01, 2022	June 02, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Cigna Group

Report date August 18, 2026 · Filed August 20, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	25,880	Reported balance After 2026-08-18 transaction · row 1 1 source row Row 1 · 2026-08-18 · Sale · Disposed 2,677 · Balance 25,880 F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.
Common Stock, $.01 Par ValueSEC Table I · non-derivative	IndirectBy 401(k)	1,451.2364	Reported balance Holding disclosure · report date 2026-08-18 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,451.2364 F2: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 4, 2026.

F2: Represents shares acquired through ongoing participation in The Cigna Group's 401(k) Plan.

FTI CONSULTING, INC

Report date June 01, 2022 · Filed June 02, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,809	Reported balance After 2022-06-01 transaction · row 1 1 source row Row 1 · 2022-06-01 · Grant · Acquired 1,492 · Balance 1,809 F1: The shares of restricted stock will vest in full on the first anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of restricted stock will vest in full on the first anniversary of the date of grant.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cigna Holding Co

Report date December 20, 2018 · Filed December 26, 2018

Section 16 reporting ended · disclosed 2018-12-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, $.25 Par ValueSEC Table I · non-derivative	Direct	Reported balance After 2018-12-20 transaction · row 1 1 source row Row 1 · 2018-12-20 · Disposition to issuer · Disposed 26,700 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.
Common Stock, $.25 Par ValueSEC Table I · non-derivative	IndirectBy 401(k)	Reported balance After 2018-12-20 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2018-12-20 · Disposition to issuer · Disposed 1,313.1308 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.73 · Expires 2023-03-05	Direct	Reported balance After 2018-12-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-12-20 · Disposition to issuer · Disposed 17,163 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $78.04 · Expires 2024-02-26	Direct	Reported balance After 2018-12-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-12-20 · Disposition to issuer · Disposed 36,316 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $120.90 · Expires 2025-02-25	Direct	Reported balance After 2018-12-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-12-20 · Disposition to issuer · Disposed 22,509 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3: This option was fully vested and exercisable at the time of the Merger.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $139.22 · Expires 2026-03-01	Direct	Reported balance After 2018-12-20 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-12-20 · Disposition to issuer · Disposed 20,342 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $149.14 · Expires 2027-02-28	Direct	Reported balance After 2018-12-20 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-12-20 · Disposition to issuer · Disposed 17,666 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $197.35 · Expires 2028-02-28	Direct	Reported balance After 2018-12-20 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-12-20 · Disposition to issuer · Disposed 14,484 · Balance 0 F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote)

F2: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30.

F3: This option was fully vested and exercisable at the time of the Merger.

F4: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option.

F5: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019.

F6: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020.

F7: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms.

F8: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 06, 2020 Filed Nov 10, 2020 23:58 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,727	$58.73	$101,426.71	Disclosure SEC source: 0001225208-20-013334 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
November 06, 2020 Filed Nov 10, 2020 23:58 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	7,531	$78.04	$587,681.59	Disclosure SEC source: 0001225208-20-013334 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
August 12, 2020 Filed Aug 13, 2020 23:40 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	393	$0.00 Strike: $58.73	$0.00	Disclosure SEC source: 0001225208-20-010599 · doc4.xml · derivative · entry 10 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,291 Underlying: Common Stock, $.01 Par Value · 393 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F5 · derivative.exercise_date: This option was granted on March 5, 2013. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 12, 2020 Filed Aug 13, 2020 23:40 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,408	$0.00 Strike: $78.04	$0.00	Disclosure SEC source: 0001225208-20-010599 · doc4.xml · derivative · entry 9 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,158 Underlying: Common Stock, $.01 Par Value · 1,408 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · derivative.exercise_date: This option was granted on February 26, 2014. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 12, 2020 Filed Aug 13, 2020 23:40 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	393	$58.73	$23,080.89	Disclosure SEC source: 0001225208-20-010599 · doc4.xml · nonDerivative · entry 5 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,539 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
August 12, 2020 Filed Aug 13, 2020 23:40 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,408	$78.04	$109,873.28	Disclosure SEC source: 0001225208-20-010599 · doc4.xml · nonDerivative · entry 4 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
August 11, 2020 Filed Aug 13, 2020 23:40 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,753	$0.00 Strike: $58.73	$0.00	Disclosure SEC source: 0001225208-20-010599 · doc4.xml · derivative · entry 8 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,684 Underlying: Common Stock, $.01 Par Value · 1,753 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F5 · derivative.exercise_date: This option was granted on March 5, 2013. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 11, 2020 Filed Aug 13, 2020 23:40 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	7,671	$0.00 Strike: $78.04	$0.00	Disclosure SEC source: 0001225208-20-010599 · doc4.xml · derivative · entry 7 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,566 Underlying: Common Stock, $.01 Par Value · 7,671 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · derivative.exercise_date: This option was granted on February 26, 2014. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
August 11, 2020 Filed Aug 13, 2020 23:40 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	9,424	$185.00	$1,743,442.83	Disclosure SEC source: 0001225208-20-010599 · doc4.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,738 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $185.00 to $185.01 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
August 11, 2020 Filed Aug 13, 2020 23:40 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,753	$58.73	$102,953.69	Disclosure SEC source: 0001225208-20-010599 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
August 11, 2020 Filed Aug 13, 2020 23:40 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	7,671	$78.04	$598,606.49	Disclosure SEC source: 0001225208-20-010599 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,409 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
May 04, 2020 Filed May 4, 2020 23:39 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	403	$0.00 Strike: $58.73	$0.00	Disclosure SEC source: 0001225208-20-007033 · doc4.xml · derivative · entry 10 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,437 Underlying: Common Stock, $.01 Par Value · 403 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · derivative.exercise_date: This option was granted on March 5, 2013. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
May 04, 2020 Filed May 4, 2020 23:39 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,464	$0.00 Strike: $78.04	$0.00	Disclosure SEC source: 0001225208-20-007033 · doc4.xml · derivative · entry 9 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,237 Underlying: Common Stock, $.01 Par Value · 1,464 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F3 · derivative.exercise_date: This option was granted on February 26, 2014. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
May 04, 2020 Filed May 4, 2020 23:39 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	403	$58.73	$23,668.19	Disclosure SEC source: 0001225208-20-007033 · doc4.xml · nonDerivative · entry 5 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
May 04, 2020 Filed May 4, 2020 23:39 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,464	$78.04	$114,243.24	Disclosure SEC source: 0001225208-20-007033 · doc4.xml · nonDerivative · entry 4 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
May 01, 2020 Filed May 4, 2020 23:39 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,742	$0.00 Strike: $58.73	$0.00	Disclosure SEC source: 0001225208-20-007033 · doc4.xml · derivative · entry 8 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,840 Underlying: Common Stock, $.01 Par Value · 1,742 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F4 · derivative.exercise_date: This option was granted on March 5, 2013. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
May 01, 2020 Filed May 4, 2020 23:39 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	7,615	$0.00 Strike: $78.04	$0.00	Disclosure SEC source: 0001225208-20-007033 · doc4.xml · derivative · entry 7 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,701 Underlying: Common Stock, $.01 Par Value · 7,615 shares Expires 2024-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. F3 · derivative.exercise_date: This option was granted on February 26, 2014. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
May 01, 2020 Filed May 4, 2020 23:39 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	9,357	$192.00	$1,796,544.00	Disclosure SEC source: 0001225208-20-007033 · doc4.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,871 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
May 01, 2020 Filed May 4, 2020 23:39 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,742	$58.73	$102,307.66	Disclosure SEC source: 0001225208-20-007033 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
May 01, 2020 Filed May 4, 2020 23:39 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	7,615	$78.04	$594,236.53	Disclosure SEC source: 0001225208-20-007033 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,486 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
April 16, 2020 Filed Apr 17, 2020 22:12 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	10,000	$185.00	$1,850,000.00	Disclosure SEC source: 0001225208-20-006593 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,871 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020. Read SEC document
March 02, 2020 Filed Mar 3, 2020 01:46 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	3,993	$182.85	$730,120.05	Disclosure SEC source: 0001225208-20-003953 · doc4.xml · nonDerivative · entry 4 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,871 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. Read SEC document
February 28, 2020 Filed Mar 3, 2020 01:46 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	2,253	$179.41	$404,210.73	Disclosure SEC source: 0001225208-20-003953 · doc4.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,864 F3 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document
February 28, 2020 Filed Mar 3, 2020 01:46 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	6,246	$0.00	$0.00	Disclosure SEC source: 0001225208-20-003953 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,117 F2 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2017-2019 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 27, 2020 Filed Mar 3, 2020 01:46 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	395	$185.76	$73,375.20	Disclosure SEC source: 0001225208-20-003953 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,871 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document
February 26, 2020 Filed Feb 29, 2020 02:27 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	15,346	$0.00 Strike: $192.02	$0.00	Disclosure SEC source: 0001225208-20-003809 · doc4.xml · derivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,346 Underlying: Common Stock, $.01 Par Value · 15,346 shares Expires 2030-02-26 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 26, 2021. Read SEC document
February 26, 2020 Filed Feb 29, 2020 02:27 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	4,193	$0.00	$0.00	Disclosure SEC source: 0001225208-20-003809 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,266 F1 · shares: These restricted shares vests in three equal annual installments beginning February 26, 2021. Read SEC document
November 19, 2019 Filed Nov 20, 2019 22:44 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	1,625	$0.00 Strike: $58.73	$0.00	Disclosure SEC source: 0001225208-19-014724 · doc4.xml · derivative · entry 6 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,582 Underlying: Common Stock, $.01 Par Value · 1,625 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F4 · derivative.exercise_date: This option was granted on March 5, 2013. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
November 19, 2019 Filed Nov 20, 2019 22:44 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	1,625	$58.73	$95,436.25	Disclosure SEC source: 0001225208-19-014724 · doc4.xml · nonDerivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,073 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. Read SEC document
November 18, 2019 Filed Nov 20, 2019 22:44 UTC	Cigna Group CI · Entity 550	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	6,956	$0.00 Strike: $58.73	$0.00	Disclosure SEC source: 0001225208-19-014724 · doc4.xml · derivative · entry 5 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,207 Underlying: Common Stock, $.01 Par Value · 6,956 shares Expires 2023-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F4 · derivative.exercise_date: This option was granted on March 5, 2013. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document
November 18, 2019 Filed Nov 20, 2019 22:44 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	6,956	$200.58	$1,395,208.74	Disclosure SEC source: 0001225208-19-014724 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,448 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $200.30 to $201.065 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
November 18, 2019 Filed Nov 20, 2019 22:44 UTC	Cigna Group CI · Entity 550	Exercise / conversionCommon Stock, $.01 Par Value	6,956	$58.73	$408,525.88	Disclosure SEC source: 0001225208-19-014724 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. Read SEC document
March 04, 2019 Filed Mar 7, 2019 00:49 UTC	Cigna Group CI · Entity 550	SaleCommon Stock, $.01 Par Value	4,450	$178.98	$796,461.00	Disclosure SEC source: 0001225208-19-004830 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,448 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2018. Read SEC document
March 01, 2019 Filed Mar 6, 2019 02:19 UTC	Cigna Group CI · Entity 550	Tax withholdingCommon Stock, $.01 Par Value	1,825	$177.85	$324,576.25	Disclosure SEC source: 0001225208-19-004742 · doc4.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,898 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting. Read SEC document
March 01, 2019 Filed Mar 6, 2019 02:19 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	6,275	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004742 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,723 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2016-2018 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:22 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	12,946	$0.00 Strike: $183.44	$0.00	Disclosure SEC source: 0001225208-19-004239 · doc4.xml · derivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,946 Underlying: Common Stock, $.01 Par Value · 12,946 shares Expires 2029-02-27 F3 · derivative.exercise_date: This option vests in three equal annual installments beginning February 27, 2020. Read SEC document
February 27, 2019 Filed Mar 2, 2019 01:22 UTC	Cigna Group CI · Entity 550	GrantCommon Stock, $.01 Par Value	3,748	$0.00	$0.00	Disclosure SEC source: 0001225208-19-004239 · doc4.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,448 F1 · shares: These restricted shares vest in three equal annual installments beginning February 27, 2020. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:46 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	14,484	Not disclosed Strike: $197.35	Not disclosed	Disclosure SEC source: 0001567619-18-008660 · doc1.xml · derivative · entry 8 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 14,484 shares Expires 2028-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7 · derivative.exercise_date: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:46 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	17,666	Not disclosed Strike: $149.14	Not disclosed	Disclosure SEC source: 0001567619-18-008660 · doc1.xml · derivative · entry 7 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 17,666 shares Expires 2027-02-28 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:46 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	20,342	Not disclosed Strike: $139.22	Not disclosed	Disclosure SEC source: 0001567619-18-008660 · doc1.xml · derivative · entry 6 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 20,342 shares Expires 2026-03-01 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F5 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:46 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	22,509	Not disclosed Strike: $120.90	Not disclosed	Disclosure SEC source: 0001567619-18-008660 · doc1.xml · derivative · entry 5 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 22,509 shares Expires 2025-02-25 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:46 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	36,316	Not disclosed Strike: $78.04	Not disclosed	Disclosure SEC source: 0001567619-18-008660 · doc1.xml · derivative · entry 4 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 36,316 shares Expires 2024-02-26 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:46 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	17,163	Not disclosed Strike: $58.73	Not disclosed	Disclosure SEC source: 0001567619-18-008660 · doc1.xml · derivative · entry 3 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.25 Par Value · 17,163 shares Expires 2023-03-05 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F4 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the Effective Time (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F3 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:46 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerCommon Stock, $.25 Par Value	1,313.1308	$0.00	$0.00	Disclosure SEC source: 0001567619-18-008660 · doc1.xml · nonDerivative · entry 2 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · By 401(k) Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F8 · shares: Represents shares acquired through ongoing participation in Cigna's 401(k) Plan and disposed of in connection with the Merger. F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · price: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document
December 20, 2018 Filed Dec 26, 2018 18:46 UTC	Cigna Holding Co CI · Entity 161580	Disposition to issuerCommon Stock, $.25 Par Value	26,700	$0.00	$0.00	Disclosure SEC source: 0001567619-18-008660 · doc1.xml · nonDerivative · entry 1 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · kind: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F1 · price: Reflects disposition in connection with the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, (continued in following footnote) F2 · price: (continued from previous footnote) with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:14 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	14,484	Not disclosed Strike: $197.35	Not disclosed	Disclosure SEC source: 0001567619-18-008699 · doc1.xml · derivative · entry 8 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,484 Underlying: Common Stock, $0.01 Par Value · 14,484 shares Expires 2028-02-28 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F8 · derivative.exercise_date: This option, which would have vested in three equal installments beginning on February 28, 2019, was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $197.35 per share on the same vesting terms. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:14 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	17,666	Not disclosed Strike: $149.14	Not disclosed	Disclosure SEC source: 0001567619-18-008699 · doc1.xml · derivative · entry 7 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,666 Underlying: Common Stock, $0.01 Par Value · 17,666 shares Expires 2027-02-28 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F7 · derivative.exercise_date: One-third of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $149.135 per share, with the remaining two-thirds of the option vesting in two equal installments on February 28, 2019 and February 28, 2020. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:14 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	20,342	Not disclosed Strike: $139.22	Not disclosed	Disclosure SEC source: 0001567619-18-008699 · doc1.xml · derivative · entry 6 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,342 Underlying: Common Stock, $0.01 Par Value · 20,342 shares Expires 2026-03-01 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F6 · derivative.exercise_date: Two-thirds of this option was vested at the time of the Merger. The option was assumed by New Cigna in the Merger and converted into an option to purchase an equal number of shares of New Cigna Common Stock for $139.22 per share, with the remaining one-third of the option vesting on March 1, 2019. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:14 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	22,509	Not disclosed Strike: $120.90	Not disclosed	Disclosure SEC source: 0001567619-18-008699 · doc1.xml · derivative · entry 5 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,509 Underlying: Common Stock, $0.01 Par Value · 22,509 shares Expires 2025-02-25 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document
December 20, 2018 Filed Dec 27, 2018 00:14 UTC	Cigna Group CI · Entity 550	GrantEmployee Stock Option (Right to Buy) · Derivative	36,316	Not disclosed Strike: $78.04	Not disclosed	Disclosure SEC source: 0001567619-18-008699 · doc1.xml · derivative · entry 4 Jones Nicole S · CIK 0001492663 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,316 Underlying: Common Stock, $0.01 Par Value · 36,316 shares Expires 2024-02-26 F1 · kind: Common Stock of Cigna Corporation, f/k/a Halfmoon Parent, Inc. ("New Cigna"), was acquired pursuant to the consummation of the mergers (collectively, the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 8, 2018, as amended by Amendment No. 1, dated as of June 27, 2018, by and among Cigna Corporation (now known as Cigna Holding Company) ("Cigna"), Express Scripts Holding Company ("Express Scripts"), Halfmoon Parent, Inc. (now known as Cigna Corporation), a direct wholly owned subsidiary of Cigna prior to the Merger ("New Cigna"), Halfmoon I, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger, and Halfmoon II, Inc., a direct wholly owned subsidiary of New Cigna prior to the Merger (the "Merger Agreement"), pursuant to which, at the effective time of the Merger (the "Effective Time"), (continued in following footnote) F2 · kind: (continued from previous footnote) (1) Halfmoon I, Inc. merged with and into Cigna, with Cigna surviving as a wholly owned subsidiary of New Cigna, and (2) Halfmoon II, Inc. merged with and into Express Scripts, with Express Scripts surviving as a wholly owned subsidiary of New Cigna. As a result of the transactions contemplated by the Merger Agreement, New Cigna became a publicly traded corporation, and former Cigna stockholders and former Express Scripts stockholders now own common stock of New Cigna. In the Merger, each share of Cigna common stock, par value $0.25 per share ("Cigna Common Stock"), was exchanged for one share of common stock, par value $0.01 per share, of New Cigna ("New Cigna Common Stock"). The closing price per share of Cigna Common Stock on December 19, 2018 (the last trading day prior to the date of the Effective Time) was $193.30. F5 · price: In accordance with the terms of the Merger Agreement, each stock option of Cigna outstanding immediately prior to the effective time of the Merger (whether vested or unvested) was automatically converted into an option to purchase shares of New Cigna Common Stock equal to the total number of shares of Cigna Common Stock subject to such option immediately prior to the closing of the Merger and at a per-share exercise price equal to the per-share exercise price of such option. F4 · derivative.exercise_date: This option was fully vested and exercisable at the time of the Merger. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.